Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Phase 1/2 Clinical Trial of HQK-1001, An Oral Fetal Hemoglobin Stimulant, In Sickle Cell Anemia

Abdullah Kutlar, MD, Kenneth I. Ataga, MD, Marvin Reid, PhD, Loray A Blair-Britt, MD, Elliott Vichinsky, MD, Lynne Neumayr, MD, Richard J. Labotka, MD, MS, Jonathan Glass, MD, FACP, Andrea Small-WIlliams, MBBS, DM(HAEM), Jeffrey Keefer, MD, PhD, Ling Shen, MD, Michael S Boosalis, PhD, Audrey Thomson, BSc, Patrick Bobbitt, BS, Wayne Wallis, MD, Elsa Johnson, MBA, Ronald J Berenson, MD, Susan P Perrine, MD

Blood (2010) 116 (21): 943.

https://doi.org/10.1182/blood.V116.21.943.943

Published: 2010

Journal Articles

Histone Deacetylase Inhibitors: Potent Inducers of Tumor Latent EBV Thymidine Kinase Induction

Douglas V Faller, Sajal K Ghosh, Susan P Perrine, MD, Robert M Williams, Ronald J Berenson, MD

Blood (2010) 116 (21): 1831.

https://doi.org/10.1182/blood.V116.21.1831.1831

Published: 2010

Journal Articles

HQK-1001 Is Well Tolerated and Augments Hemoglobin F and Hemoglobin Levels In Patients with Beta Thalassemia Intermedia

Suthat Fuchareon, MD, Adlette C. Inati, MD, Noppadol Siritanaratkul, MD, Suzanne Koussa, MD, Ali Taher, MD, Michael S Boosalis, PhD, Swee Lay Thein, DSc, FRCP, MB, BS, FRCPath, Wayne Wallis, MD, Patrick Bobbitt, BS, Audrey Thomson, BSc, Elsa Johnson, MBA, Ronald J Berenson, MD, Susan P Perrine, MD

Blood (2010) 116 (21): 4280.

https://doi.org/10.1182/blood.V116.21.4280.4280

Published: 2010

Journal Articles

PK11195, a Ligand of the Peripheral Benzodiazepine Receptor, Inhibits Myeloma Cell Growth In Vitro and Chemosensitizes Myeloma Cells In Vivo in SCID-hu Models of Human Multiple Myeloma.

Richard A. Campbell, Eric Sanchez, Haiming Chen, MD, PhD, Lauren Turker, Olivia Trac, Mingjie Li, Dror Shalitin, PhD, Melinda S. Gordon, PhD, Shen Pang, PhD, Benjamin Bonavida, PhD, Jonathan Said, MD, Ronald J. Berenson, MD, James R. Berenson, MD

Blood (2006) 108 (11): 3459.

https://doi.org/10.1182/blood.V108.11.3459.3459

Published: 2006

Journal Articles

Naive and Ex Vivo Activated Human T Cells Generate Consistent Engraftment and Lethal Graft-Versus-Host Disease (GvHD) in NOD SCID β 2M Null Mice: A New Xenogeneic Model for GvHD.

Bruno Nervi, MD, Michael P. Rettig, PhD, Julie K. Ritchey, Gerhard Bauer, Jon Walker, Dave Hess, PhD, Phillip E. Herrbrich, Mark Bonyhadi, PhD, Ronald J. Berenson, MD, Jan A. Nolta, PhD, John F. DiPersio, MD, PhD

Blood (2005) 106 (11): 3106.

https://doi.org/10.1182/blood.V106.11.3106.3106

Published: 2005

Journal Articles

Combined Cytoreduction and Infusion of Anti-CD3/Anti-CD28 Bead-Activated T Cells Prevent Diabetes in NOD Mice.

Ronald J. Berenson, MD, Sarah A. Long, PhD, Mark L. Bonyhadi, PhD

Blood (2005) 106 (11): 3036.

https://doi.org/10.1182/blood.V106.11.3036.3036

Published: 2005

Journal Articles

Anti-CD3/Anti-CD28 Bead-Activated T Cells Facilitate Engraftment of Murine Histoincompatible Allogeneic Transplants after Low-Dose Radiation.

Ronald J. Berenson, MD, Julie K. Ritchey, PhD, Mark L. Bonyhadi, PhD, John F. DiPersio, MD

Blood (2005) 106 (11): 5221.

https://doi.org/10.1182/blood.V106.11.5221.5221

Published: 2005

Journal Articles

A Phase I/II Study of Xcellerated T Cells ™ after Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma.

David Siegel, MD, Ravi Vij, MD, Robert A. Vescio, MD, Ivan M. Borrello, MD, Thomas G. Martin, MD, James R. Berenson, MD, Christophe Ferrand, PhD, Fatimit Janmohamed, Ronald J. Berenson, MD, Mark W. Frohlich, MD

Blood (2004) 104 (11): 925.

https://doi.org/10.1182/blood.V104.11.925.925

Published: 2004

Journal Articles

Restoring a Normal T Cell Receptor Repertoire Using the Xcellerate™ Technology: A Potential Therapeutic Strategy for Patients with Hematological Disorders and Autoimmune Diseases.

Alice Long, PhD, Jahan Khalili, Joy Lawrence, Ronald J. Berenson, MD, Mark L. Bonyhadi, PhD

Blood (2004) 104 (11): 3853.

https://doi.org/10.1182/blood.V104.11.3853.3853

Published: 2004

Journal Articles

Activated and Expanded T Cells for Potential Therapy of Patients with Autoimmune Diseases.

Alice Long, PhD, Mark Bonyhadi, PhD, Christophe Ferrand, PhD, Mark Frohlich, MD, Ronald J. Berenson, MD

Blood (2004) 104 (11): 3854.

https://doi.org/10.1182/blood.V104.11.3854.3854

Published: 2004

Journal Articles

Biological Characteristics of T Cells from CD4 Idiopathic Lymphocytopenia Patients Activated and Expanded Using Xcellerate™ Technology.

Joy Lawrence, Mark L. Bonyhadi, PhD, Charlotte Cunningham-Rundles, MDPhD, Ronald J. Berenson, MD, Alice Long, PhD

Blood (2004) 104 (11): 3834.

https://doi.org/10.1182/blood.V104.11.3834.3834

Published: 2004

Journal Articles

A Phase II Study of Xcellerated T Cells™ in Patients with Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma (NHL).

Blood (2004) 104 (11): 4640.

https://doi.org/10.1182/blood.V104.11.4640.4640

Published: 2004

Journal Articles

A Phase I/II Trial of Xcellerated T Cells™ in Patients with Chronic Lymphocytic Leukemia.

Januario E. Castro, MD, William G. Wierda, MD, PhD, Thomas J. Kipps, MD, PhD, Michael J. Keating, MBBS, Jan Bole, RN, Blanche Anderson, Jayne Meyer, RN, Mark Bonyhadi, PhD, Ronald J. Berenson, MD, Mark W. Frohlich, MD

Blood (2004) 104 (11): 2508.

https://doi.org/10.1182/blood.V104.11.2508.2508

Published: 2004

NARROW

Phase 1/2 Clinical Trial of HQK-1001, An Oral Fetal Hemoglobin Stimulant, In Sickle Cell Anemia

Histone Deacetylase Inhibitors: Potent Inducers of Tumor Latent EBV Thymidine Kinase Induction

HQK-1001 Is Well Tolerated and Augments Hemoglobin F and Hemoglobin Levels In Patients with Beta Thalassemia Intermedia

PK11195, a Ligand of the Peripheral Benzodiazepine Receptor, Inhibits Myeloma Cell Growth In Vitro and Chemosensitizes Myeloma Cells In Vivo in SCID-hu Models of Human Multiple Myeloma.

Naive and Ex Vivo Activated Human T Cells Generate Consistent Engraftment and Lethal Graft-Versus-Host Disease (GvHD) in NOD SCID β 2M Null Mice: A New Xenogeneic Model for GvHD.

Combined Cytoreduction and Infusion of Anti-CD3/Anti-CD28 Bead-Activated T Cells Prevent Diabetes in NOD Mice.

Anti-CD3/Anti-CD28 Bead-Activated T Cells Facilitate Engraftment of Murine Histoincompatible Allogeneic Transplants after Low-Dose Radiation.

A Phase I/II Study of Xcellerated T Cells ™ after Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma.

Restoring a Normal T Cell Receptor Repertoire Using the Xcellerate™ Technology: A Potential Therapeutic Strategy for Patients with Hematological Disorders and Autoimmune Diseases.

Activated and Expanded T Cells for Potential Therapy of Patients with Autoimmune Diseases.

Biological Characteristics of T Cells from CD4 Idiopathic Lymphocytopenia Patients Activated and Expanded Using Xcellerate™ Technology.

A Phase II Study of Xcellerated T Cells™ in Patients with Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma (NHL).

A Phase I/II Trial of Xcellerated T Cells™ in Patients with Chronic Lymphocytic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only